Journal of Leukemia
Open Access

Exploring the Efficacy and Risks of Allogeneic Stem Cell Transplantation in Leukemia

Daniel Robinson^{* *}Correspondence: Daniel Robinson, Department of Immunology, University of Latvia, Riga,, Latvia, Email:

Author info »

Description

Leukemia is a type of cancer that affects the blood and bone marrow, characterized by the rapid proliferation of abnormal white blood cells. Treatments for leukemia vary, but one of the most effective options for patients, especially those with aggressive or relapsed leukemia, is allogeneic Stem Cell Transplantation (allo-SCT). Allo-SCT involves replacing a patient’s diseased bone marrow with healthy stem cells from a genetically compatible donor. This procedure holds the potential to cure leukemia but also comes with significant risks and complications. This article will explore the scientific principles, process, benefits, risks, and evolving landscape of allogeneic stem cell transplantation in leukemia treatment. Allogeneic stem cell transplantation involves infusing healthy stem cells from a donor into a patient with leukemia to rebuild their bone marrow. These stem cells can develop into all types of blood cells, including red blood cells, white blood cells, and platelets, enabling the recipient’s body to restore normal hematopoiesis (blood cell formation) after aggressive treatments like chemotherapy or radiation. Allogeneic transplantation is preferred in leukemia because donor cells can induce the "Graft-Versus- Leukemia" (GVL) effect, where the donor's immune cells target and eliminate residual leukemia cells, providing an immunological advantage over autologous transplants.

For a successful allogeneic stem cell transplant, finding a compatible donor is importance. The most critical aspect of compatibility is the match of Human Leukocyte Antigens (HLA). These proteins are present on the surface of white blood cells and help the immune system distinguish between self and nonself. A close HLA match between the donor and recipient reduces the risk of transplant rejection and complications such as Graft-Versus-Host Disease (GVHD). The best chance for an HLA match is usually with a sibling, as there is a 25% chance of inheriting the same HLA from both parents. If no sibling match is available, a search for unrelated donors through international bone marrow registries is conducted. Modern advances in HLA typing have improved the success rate of finding suitable unrelated donors. In cases where a full match is unavailable, partially matched family members (haploidentical transplants) can also serve as donors, although these transplants carry higher risks of complications. Allo-SCT is a complex process that consists of several stages, each critical to the procedure’s success.

Before the transplant, the patient undergoes intensive chemotherapy and/or radiation therapy, known as conditioning. The goal is to destroy the patient’s existing bone marrow (including leukemia cells), suppress their immune system to prevent graft rejection, and create space for the new donor cells. A less aggressive regimen used for older or frail patients. Stem cells are collected from the donor’s bone marrow or blood. In peripheral blood stem cell collection, donors receive medications to increase stem cell production and mobilization into the bloodstream before collection. Bone marrow extraction involves harvesting directly from the bone marrow, typically from the pelvis. The harvested stem cells are infused intravenously into the patient. Over time, the donor’s stem cells migrate to the bone marrow and begin producing new, healthy blood cells. Engraftment—the process by which the new stem cells start producing white blood cells, red blood cells, and platelets— usually occurs within two to four weeks after the transplant.

Patients are closely monitored for complications such as infections, GVHD, and graft failure. They are often placed in isolation during the immediate post-transplant period due to the weakened immune system. Supportive care, including antibiotics, antiviral drugs, and blood transfusions, is provided to manage risks.

One of the most significant advantages of allo-SCT is the Graft- Versus-Leukemia (GVL) effect. Donor immune cells recognize and attack residual leukemia cells in the patient’s body, contributing to long-term remission. The GVL effect is a unique benefit of allogeneic transplantation and is crucial in preventing relapse, especially in high-risk or relapsed leukemia cases. For certain types of leukemia, including Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), allogeneic stem cell transplantation offers curative potential. Many patients who undergo successful allo-SCT remain disease-free for extended periods, with some achieving complete remission. Allo-

SCT is often considered for patients with relapsed or refractory leukemia, where other treatment modalities have failed. It provides a chance for remission in cases where chemotherapy or targeted therapies are insufficient. Despite its curative potential, allogeneic stem cell transplantation carries significant risks.

GVHD occurs when the donor’s immune cells attack the recipient’s tissues, recognizing them as foreign. It can affect various organs, including the skin, liver, gastrointestinal tract, and lungs. Occurs within the first 100 days post-transplant and primarily affects the skin, liver, and intestines. Can occur months or years after the transplant, leading to long-term complications and impaired quality of life. Due to the weakened immune system during the engraftment period and the use of immunosuppressive drugs to prevent GVHD, patients are highly susceptible to bacterial, viral, and fungal infections. Close monitoring and prophylactic treatment are essential in managing infections. Graft failure, where the donor’s cells do not engraft or are rejected by the patient’s immune system, is a serious complication that can lead to death if not addressed promptly. This can result from inadequate conditioning, poor HLA matching, or other immune-related factors. Although allo-SCT offers curative potential, relapse of leukemia remains a possibility. Relapse rates vary depending on factors such as the type of leukemia, the patient’s response to conditioning, and the presence of GVHD. Some patients may undergo a second transplant or receive donor lymphocyte infusions to boost the GVL effect.

Conclusion

Allogeneic stem cell transplantation remains a cornerstone in the treatment of high-risk and relapsed leukemia. Its unique ability to harness the donor’s immune system through the graftversus- leukemia effect offers curative potential that is unmatched by other treatments. However, allo-SCT is not without risks, and complications such as GVHD, infections, and graft failure require careful management. Advances in donor selection, conditioning regimens, and supportive care have expanded the use of allo-SCT to a broader patient population. As research continues, allo-SCT will likely be further refined, potentially improving outcomes for leukemia patients and making it a more accessible and safer option.